Real Life Evaluation of SGLT2 Use in Type 1 Diabetes
Real Life Evaluation of SGLT2 Use in Type 1 Diabetes
The primary aim of the study is to prospectively monitor the risk of diabetic ketoacidosis
 (DKA) during treatment with sodium-glucose cotransporter 2 (SGLT2) inhibitors in type 1
 diabetes after the treatment has become available as an adjunct therapy for people with type
 1 diabetes.
SGLT2 inhibitors have recently been approved for treatment of type 1 diabetes. SGLT2
 inhibitors affect renal glucose transport and promotes glucose excretion in the urine. This
 have attractive effects, notably by lowering of blood glucose without any increased risk of
 hypoglycemia as well as a reduction in body weight. Since the risk of hypoglycemia and weight
 gain during intensification of insulin treatment is a significant barrier for optimal
 glycemic control, SGLT2 inhibitors could be an attractive adjunct therapy in type 1 diabetes.
 Furthermore, SGLT2 inhibitors have beneficial cardiovascular and renal effects in persons
 with type 2 diabetes. This may also benefit persons with type 1 diabetes. However, the major
 limitation for an universal use of SGLT2 inhibitors in type 1 diabetes is a substantial
 increase in ketogenesis and the risk of DKA. DKA remain a substantial cause of morbidity and
 mortality in persons with type 1 diabetes.

 Since no data exist on the risk of DKA during SGLT2 inhibition outside the randomized
 controlled trials, the investigators will initiate a nationwide monitoring study on the use
 of SGLT2 inhibitors in type 1 diabetes. This will ensure follow-up on the efficacy, safety
 and patient-reported outcome measures for SGLT2 inhibitors treatment of type 1 diabetes in
 real-world clinical practice.
Inclusion Criteria:

 -  All patiens with type 1 diabetes on SGLT2 inhibitor treatment or where this treatment
 is planned.

 Exclusion Criteria:

 -  None